RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B LIGAND (RANKL) AND OSTEOPROTEGERIN (OPG) IN RADICULAR CYSTS, DENTIGEROUS CYSTS AND HEALTHY VOLUNTEERS

被引:0
|
作者
Pechalova, Petia F. [1 ]
Poriazova, Elena G. [2 ]
Pavlov, Nikolai V. [3 ]
Gospodinov, Dimitar L. [1 ]
机构
[1] Med Univ Plovdiv, Dept Oral Surg, 3 Hristo Botev Blvd, Plovdiv 4003, Bulgaria
[2] Med Univ Plovdiv, Dept Pathol, 15A Vasil Aprilov St, Plovdiv 4002, Bulgaria
[3] 15A Lozarska St, Plovdiv 4003, Bulgaria
来源
关键词
OPG; RANKL; radicular cyst; dentigerous cyst; OSTEOCLASTOGENESIS-INHIBITORY FACTOR; DIFFERENTIATION FACTOR; APICAL PERIODONTITIS; BONE; EXPRESSION; GRANULOMAS; CYTOKINE; DISEASE; LESIONS;
D O I
暂无
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Radicular and dentigerous cysts are the two most common histological types of jaw cysts. Their growth is related to bone loss. The process of bone destruction takes place under the action of cytokines receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG). The objective of this study is to examine how the concentration of RANKL and OPG is changing in patients with both types of cysts and healthy volunteers. The study includes 15 patients with radicular cysts, 15 with dentigerous cysts and 30 healthy control volunteers. The study investigated serum concentration of sRANKL and OPG in patients and volunteers, as well as the expression of RANKL and OPG in the epithelial sac of the cysts. The results showed elevated sRANKL levels in patients with cysts compared to the healthy volunteers. Serum OPG levels in patients with radicular cysts were higher compared to those of the control group. RANKL in the epithelial sac of dentigerous cysts was higher compared to the epithelial sac of radicular cysts. To precisely specify the role of cytokines RANKL and OPG in the process of bone destruction in radicular and dentigerous cysts, further studies shall be performed.
引用
收藏
页码:385 / 392
页数:10
相关论文
共 50 条
  • [21] The Role of the Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Vascular Diseases: A Therapeutic Approach
    Celebi Torabfam, Gizem
    Porsuk, Melis Hazal
    ANGIOLOGY, 2024,
  • [22] EFFECT OF FLUORIDE ON OSTEOCLAST FORMATION AT VARIOUS LEVELS OF RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B LIGAND (RANKL)
    Pei, Junrui
    Gao, Yanhui
    Li, Bingyun
    Zhou, Lingwang
    Zhang, Zhiyi
    Sun, Dianjun
    FLUORIDE, 2012, 45 (02) : 86 - 93
  • [23] Osteoprotective Effect of Cimiracemate in Glucocorticoid-Induced Osteoporosis by Osteoprotegerin/Receptor Activator of Nuclear Factor κB/Receptor Activator of Nuclear Factor Kappa-B Ligand Signaling
    Ding, Zheng
    Shi, Huifeng
    Yang, Wei
    PHARMACOLOGY, 2019, 103 (3-4) : 163 - 172
  • [24] Increased Concentration of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Predate Onset of Rheumatoid Arthritis
    Johansson, Linda
    Arlestig, Lisbeth
    Kokkonen, Heidi
    Rantapaa-Dahlqvist, Solbritt
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [25] Immunohistochemical Detection of Receptor Activator Nuclear κB Ligand and Osteoprotegerin in Odontogenic Cysts and Tumors
    de Matos, Felipe Rodrigues
    de Moraes, Maiara
    das Neves Silva, Emilia Beatriz
    Galvao, Hebel Cavalcanti
    Freitas, Roseana de Almeida
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2013, 71 (11) : 1886 - 1892
  • [26] Serum osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) in healthy United States children and in children with cystic fibrosis.
    Price, HE
    Langman, CB
    Arwady, A
    McColley, S
    Lyons, K
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S469 - S469
  • [27] The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review
    Malliga, Daniela-Eugenia
    Wagner, Doris
    Fahrleitner-Pammer, Astrid
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2011, 161 (23-24) : 565 - 570
  • [28] Relationship of serum osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), and 2-year change in bone mineral density, (BMD) in systemic lupus erythematosus (SLE).
    Lee, C
    Almagor, O
    Rhew, EY
    Eksarko, P
    McKinney, K
    Chadha, AB
    Dunlop, DD
    Spies, S
    Pope, RM
    Ramsey-Goldman, R
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S305 - S305
  • [29] Influence of Hormone Replacement Therapy on Osteoprotegerin and Receptor Activator of Nuclear Factor Kappa-B Ligand Concentrations in Menopausal Women
    Rahnama, Mansur
    Jastrzebska-Jamrogiewicz, Izabela
    Jamrogiewicz, Rafal
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2013, 33 (09): : 485 - 492
  • [30] Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Marginal Jawbone Loss Predates the Onset of Rheumatoid Arthritis
    Kindstedt, Elin
    Johansson, Linda
    Palmqvist, Py
    Holm, Cecilia Koskinen
    Kokkonen, Heidi
    Johansson, Ingegerd
    Lundberg, Pernilla
    Rantapaa-Dahlqvist, Solbritt
    ARTHRITIS & RHEUMATOLOGY, 2017, 69